Skip to main content
SpringerLink
Log in

Closeout

  • Chapter
Fundamentals of Clinical Trials

  • 113k Accesses

Abstract

The closeout phase starts with the final follow-up visit of the first participant enrolled and lasts until all analyses have been completed. It is evident that well before the scheduled end of the trial, there needs to be a detailed plan for this phase if the study is to be completed in an orderly manner. Importantly, one must be prepared to implement or modify this plan prior to the scheduled termination since unexpected trial results, either beneficial or harmful, may require the trial to be stopped early.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Shepherd R, Macer JL, Grady D. Planning for closeout--from day one. Contemp Clin Trials 2008;29:136–139.

    Google Scholar 

  2. Pressel SL, Davis BR, Wright JT, et al; ALLHAT Collaborative Research Group. Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trials 2001;22:29–41.

    Google Scholar 

  3. Granger CB, Alexander JH, McMurray JJ, et. al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992.

    Google Scholar 

  4. Collins JF, Howell CL, Horney RA; Digitalis Investigation Group Investigators. Determination of vital status at the end of the DIG trial. Control Clin Trials 2003;24:726–730.

    Article  Google Scholar 

  5. Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9–19.

    Google Scholar 

  6. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. Briefing Information for the May 23, 2012 Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm304754.htm. Accessed January 13, 2015.

  7. Bai S, Grant S, Marciniak T; U.S. Food and Drug Administration. Rivaroxaban for ACS sNDA 202439/S-002. Cardiovascular and Renal Drugs Advisory Committee Meeting, January 16, 2014 slide presentation. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM386282.pdf. Accessed January 13, 2015.

  8. Bristow MR, Saxon LA, Boehmer J, et al; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–2150.

    Google Scholar 

  9. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008;372:1756–1764.

    Article  Google Scholar 

  10. Panel on Handling Missing Data in Clinical Trials, Committee on National Statistics, Division of Behavioral and Social Sciences and Education, National Research Council of the National Academies. The Prevention and Treatment of Missing Data in Clinical Trials. National Academies Press, Washington, DC. January 4, 2011.

    Google Scholar 

  11. Fisher B, Redmond CK. Fraud in breast-cancer trials. N Engl J Med 1994;330:1458–1462.

    Article  Google Scholar 

  12. Buyse M, George SL, Evans S, et al. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Stat Med 1999;18:3435–3451.

    Article  Google Scholar 

  13. Sheldon T. Dutch neurologist found guilty of fraud after falsifying 438 case records. BMJ 2002;325:734.

    Article  Google Scholar 

  14. Ross DB. The FDA and the case of Ketek. N Engl J Med 2007;356:1601–1604.

    Google Scholar 

  15. POISE Study Group, Devereaux PJ, Yang H, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839–1847 (Webappendix 1).

    Google Scholar 

  16. Rostami R, Nahm M, Pieper CF. What can we learn from a decade of database audits? The Duke Clinical Research Institute experience, 1997--2006. Clin Trials 2009;6:141–150.

    Google Scholar 

  17. Eisenstein EL, Lemons PW 2nd, Tardiff BE, et al. Reducing the cost of phase III cardiovascular clinical trials. Am Heart J 2005;149:482–488.

    Article  Google Scholar 

  18. Eisenstein EL, Collins R, Cracknell BS, et al. Sensible approaches for reducing clinical trial costs. Clin Trials 2008;5:75–84.

    Article  Google Scholar 

  19. Zarin DA, Tse T, Williams RJ, et al. The ClinicalTrials.gov results database--update and key issues. N Engl J Med 2011;364:852–860.

    Google Scholar 

  20. Gordon D, Taddei-Peters W, Mascette A, et al. Publication of trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med 2013;369:1926–1934.

    Article  Google Scholar 

  21. Trials. http://www.trialsjournal.com.

  22. Hrynaszkiewicz I, Altman DG. Towards agreement on best practice for publishing raw clinical trial data. Trials 2009;10:17.

    Article  Google Scholar 

  23. Krumholz HM, Peterson ED. Open access to clinical trials data. JAMA 2014;312:1002–1003.

    Article  Google Scholar 

  24. Reporting clinical trials: message and medium. Lancet 1994;344:347–348.

    Google Scholar 

  25. National Institutes of Health. Final NIH statement on sharing research data. February 26, 2003. Available at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03–032.html. Accessed January 13, 2015.

  26. National Institutes of Health. NIH Data Sharing Policy. Available at: http://grants.nih.gov/grants/policy/data_sharing. Accessed January 13, 2015.

  27. National Institutes of Health. News & Events website. Available at: www.NIH.gov/news. Accessed January 13, 2015.

  28. US Department of Health and Human Services. NIH News website. National Institutes of Health. NIH halts use of COX-2 inhibitor in large cancer prevention trial. December 17, 2004. Available at: http://www.nih.gov/news/pr/dec2004/od-17.htm. Accessed January 13, 2015.

  29. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071–1080.

    Article  Google Scholar 

  30. National Institutes of Health, U.S. National Library of Medicine. MedlinePlus website. Available at: http://www.nlm.nih.gov/medlineplus/news. Accessed January 13, 2015.

  31. U.S. Food and Drug Administration, U.S. Department of Health and Human Services. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Available at: http://www.fda.gov/medwatch. Accessed January 13, 2015.

  32. U.S. Food and Drug Administration, U.S. Department of Health and Human Services. FDA Drugs website. Available at: http://www.fda.gov/Drugs. Access January 13, 2015.

  33. Zarin DA, Ide NC, Tse T, et al. Issues in the registration of clinical trials. JAMA 2007;297:2112–2120.

    Article  Google Scholar 

  34. World Health Organization. International Clinical Trials Registry Platform (ICTRP) website. Available at: http://www.who.int/ictrp/en/. Accessed January 13, 2015.

  35. Zarin DA, Tse T. Medicine. Moving toward transparency of clinical trials. Science 2008;319;1340–1342.

    Article  Google Scholar 

  36. Granger CB, Lopes RD, Hanna M, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 2015;169:25-30.

    Article  Google Scholar 

  37. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284:878–881.

    Article  Google Scholar 

  38. Paganini-Hill A, Ross RK, Henderson BE. Endometrial cancer and patterns of use of estrogen replacement therapy: a cohort study. Br J Cancer 1989;59:445–447.

    Article  Google Scholar 

  39. Meador KJ, Baker GA, Browning N, et al; NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009;360:1597–1605.

    Article  Google Scholar 

  40. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 1978;40:1069–1118.

    Google Scholar 

  41. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360–381.

    Google Scholar 

  42. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1980;2:379–385.

    Google Scholar 

  43. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245–1255.

    Article  Google Scholar 

  44. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 1982;248:1465–1477.

    Google Scholar 

  45. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. Findings related to a priori hypotheses of the trial. The Multiple Risk Factor Intervention Trial Research Group. JAMA 1990;263:1795–1801.

    Google Scholar 

  46. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361:1843–1848.

    Article  Google Scholar 

  47. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203–212.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. North Bethesda, MD, USA

    Lawrence M. Friedman

  2. Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Curt D. Furberg

  3. Department Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA

    David L. DeMets

  4. Department of Biostatistics, Wake Forest School of Medicine, Winston-Salem, NC, USA

    David M. Reboussin

  5. Department of Medicine, Duke University, Durham, NC, USA

    Christopher B. Granger

Authors
  1. Lawrence M. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Curt D. Furberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David L. DeMets
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David M. Reboussin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christopher B. Granger
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Friedman, L.M., Furberg, C.D., DeMets, D.L., Reboussin, D.M., Granger, C.B. (2015). Closeout. In: Fundamentals of Clinical Trials. Springer, Cham. https://doi.org/10.1007/978-3-319-18539-2_19

Download citation

Publish with us

Policies and ethics

Search

Navigation